1100995-41-2

Basic information

• Product Name: 4'-{[2-n-propyl-4-methyl-6-(1-methylbenzoimidazol-2-yl)benzoimidazol-1-yl]methyl}-2-(1-triphenylmethylimidazole-2-yl)biphenyl
• Synonyms: 4'-{[2-n-propyl-4-methyl-6-(1-methylbenzoimidazol-2-yl)benzoimidazol-1-yl]methyl}-2-(1-triphenylmethylimidazole-2-yl)biphenyl
• CAS NO: 1100995-41-2
• Molecular Weight: 778.999
• Mol File: 1100995-41-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4'-{[2-n-propyl-4-methyl-6-(1-methylbenzoimidazol-2-yl)benzoimidazol-1-yl]methyl}-2-(1-triphenylmethylimidazole-2-yl)biphenyl(CAS DataBase Reference)
• NIST Chemistry Reference: 4'-{[2-n-propyl-4-methyl-6-(1-methylbenzoimidazol-2-yl)benzoimidazol-1-yl]methyl}-2-(1-triphenylmethylimidazole-2-yl)biphenyl(1100995-41-2)
• EPA Substance Registry System: 4'-{[2-n-propyl-4-methyl-6-(1-methylbenzoimidazol-2-yl)benzoimidazol-1-yl]methyl}-2-(1-triphenylmethylimidazole-2-yl)biphenyl(1100995-41-2)

Safety Data

• Hazardous Substances Data: 1100995-41-2(Hazardous Substances Data)

Upstream product

• 1100995-40-1 1-triphenylmethyl-2-[4'-(bromomethyl)biphenyl-2-yl]-1H-imidazole 
• 152628-02-9 2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)benzimidazole 

Downstream Products

• 1100995-32-1 4'-{[2-n-propyl-4-methyl-6-(1-methylbenzoimidazol-2-yl)benzoimidazol-1-yl]methyl}-2-(1H-imidazole-2-yl)biphenyl 

Relevant articles and documents

Synthesis and biological activities of novel nonpeptide angiotensin II receptor antagonists based on benzimidazole derivatives bearing a heterocyclic ring

A series of benzimidazole derivatives bearing a heterocyclic ring imidazole (1), 5-chloroimidazole (2), 1,2,4-triazol (3), and imidazoline (4) were synthesized and evaluated for angiotensin II antagonistic activities. The synthetic compounds 1-4 were biologically evaluated in vitro using an AT1 receptor binding assay, where compounds 1 and 3 provided weak binding affinity, compound 2 showed moderate binding affinity, and compound 4 showed good binding affinity. Moreover, compound 4 was found to be almost equipotent with telmisartan in vivo biological evaluation study.